Hypopituitarism after Gamma Knife radiosurgery for pituitary adenomas: a multicenter, international study.
Cushing’s disease
acromegaly
hypopituitarism
pituitary adenoma
stereotactic radiosurgery
Journal
Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
received:
20
02
2018
accepted:
16
05
2018
medline:
2
8
2019
pubmed:
2
8
2019
entrez:
2
8
2019
Statut:
epublish
Résumé
Recurrent or residual adenomas are frequently treated with Gamma Knife radiosurgery (GKRS). The most common complication after GKRS for pituitary adenomas is hypopituitarism. In the current study, the authors detail the timing and types of hypopituitarism in a multicenter, international cohort of pituitary adenoma patients treated with GKRS. Seventeen institutions pooled clinical data obtained from pituitary adenoma patients who were treated with GKRS from 1988 to 2016. Patients who had undergone prior radiotherapy were excluded. A total of 1023 patients met the study inclusion criteria. The treated lesions included 410 nonfunctioning pituitary adenomas (NFPAs), 262 cases of Cushing's disease (CD), and 251 cases of acromegaly. The median follow-up was 51 months (range 6-246 months). Statistical analysis was performed using a Cox proportional hazards model to evaluate factors associated with the development of new-onset hypopituitarism. At last follow-up, 248 patients had developed new pituitary hormone deficiency (86 with NFPA, 66 with CD, and 96 with acromegaly). Among these patients, 150 (60.5%) had single and 98 (39.5%) had multiple hormone deficiencies. New hormonal changes included 82 cortisol (21.6%), 135 thyrotropin (35.6%), 92 gonadotropin (24.3%), 59 growth hormone (15.6%), and 11 vasopressin (2.9%) deficiencies. The actuarial 1-year, 3-year, 5-year, 7-year, and 10-year rates of hypopituitarism were 7.8%, 16.2%, 22.4%, 27.5%, and 31.3%, respectively. The median time to hypopituitarism onset was 39 months.In univariate analyses, an increased rate of new-onset hypopituitarism was significantly associated with a lower isodose line (p = 0.006, HR = 8.695), whole sellar targeting (p = 0.033, HR = 1.452), and treatment of a functional pituitary adenoma as compared with an NFPA (p = 0.008, HR = 1.510). In multivariate analyses, only a lower isodose line was found to be an independent predictor of new-onset hypopituitarism (p = 0.001, HR = 1.38). Hypopituitarism remains the most common unintended effect of GKRS for a pituitary adenoma. Treating the target volume at an isodose line of 50% or greater and avoiding whole-sellar radiosurgery, unless necessary, will likely mitigate the risk of post-GKRS hypopituitarism. Follow-up of these patients is required to detect and treat latent endocrinopathies.
Identifiants
pubmed: 31369225
doi: 10.3171/2018.5.JNS18509
pmc: PMC9535685
mid: NIHMS1056011
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1188-1196Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Références
Neurosurg Focus. 2003 May 15;14(5):e10
pubmed: 15669806
Neurosurg Focus. 2003 May 15;14(5):e12
pubmed: 15669808
Eur J Endocrinol. 2017 Jul;177(1):R13-R26
pubmed: 28351913
Acta Neurochir (Wien). 2004 Jan;146(1):27-35
pubmed: 14740262
J Neurosurg. 2010 Dec;113 Suppl:153-59
pubmed: 21222294
J Clin Endocrinol Metab. 2008 Oct;93(10):3717-26
pubmed: 18682516
Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24
pubmed: 15135792
J Neurosurg. 2002 Dec;97(5 Suppl):415-21
pubmed: 12507067
Acta Chir Scand. 1951 Dec 13;102(4):316-9
pubmed: 14914373
Endocrine. 2017 Apr;56(1):33-42
pubmed: 27817141
Neurosurgery. 2010 Jul;67(1):27-32; discussion 32-3
pubmed: 20559089
J Neurosurg. 2006 Jan;104(1):157-62
pubmed: 16509161
Clin Endocrinol (Oxf). 1999 May;50(5):561-7
pubmed: 10468920
Neurosurgery. 2013 Apr;72(4):630-7; 636-7
pubmed: 23277375
Cancer. 2004 Aug 1;101(3):613-9
pubmed: 15274075
Neurosurgery. 2011 Aug;69(2):284-93
pubmed: 21792138
Clin Endocrinol (Oxf). 2001 Dec;55(6):735-40
pubmed: 11895214
J Clin Endocrinol Metab. 2006 May;91(5):1796-801
pubmed: 16507632
Pituitary. 2009;12(3):211-6
pubmed: 19152112
Nat Rev Endocrinol. 2010 Apr;6(4):214-23
pubmed: 20177403
J Neurosurg. 2002 Dec;97(5 Suppl):408-14
pubmed: 12507066
Neurosurgery. 2003 Jul;53(1):51-9; discussion 59-61
pubmed: 12823873
J Neurosurg. 2005 Apr;102(4):678-91
pubmed: 15871511
Nat Clin Pract Endocrinol Metab. 2009 Feb;5(2):88-99
pubmed: 19165221
J Neurosurg. 2002 Sep;97(3):525-30
pubmed: 12296634
Q J Med. 1989 Feb;70(262):145-60
pubmed: 2594955
Clin Endocrinol (Oxf). 2006 Jul;65(1):51-8
pubmed: 16817819
Neurosurgery. 2008 Oct;63(4):709-18; discussion 718-9
pubmed: 18981881
Pituitary. 2003 Sep;6(2):81-7
pubmed: 14703017
Acta Neuropathol. 2017 Oct;134(4):521-535
pubmed: 28821944
Eur J Endocrinol. 2005 Mar;152(3):379-87
pubmed: 15757854
Neurosurgery. 2014 Apr;74(4):360-4; discussion 364-5; quiz 365-6
pubmed: 24448185
J Neurosurg. 2011 Feb;114(2):303-9
pubmed: 20540596
J Neurosurg. 2002 Dec;97(5 Suppl):429-32
pubmed: 12507069
Neurosurgery. 2014 Sep;75(3):227-37; discussion 237
pubmed: 24867204
N Engl J Med. 1994 Jun 9;330(23):1651-62
pubmed: 8043090
Endocr Dev. 2009;15:1-24
pubmed: 19293601
J Neurosurg. 2007 May;106(5):833-8
pubmed: 17542527
Neurosurg Rev. 2007 Jul;30(3):167-75; discussion 175-6
pubmed: 17483973